IPSC

#3144
Century Therapeutics, Inc. - Common Stock
2.0 3 USD
-0.09%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
2.03
2.03
Jahresspanne
0.44
3.03
Tagesänderung
-8.97%
Monatliche Änderung
-6.88%
6 month change
-9.38%
Jahresänderung
+314.29%
Vorheriger Schlusskurs
2.2 3
Open
2.0 3
Tief
2.0 3
Hoch
2.0 3
Volumen
34
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Century Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Century Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Century Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K

Century Therapeutics, Inc. current report, Q4 FY2022

Full document

Century Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Century Therapeutics, Inc. on November 10, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "IPSC". The filing serves as a Regulation FD disclosure to update information previously provided in an investor slide presentation.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of updated presentation materials rather than a financial statement release.

Material Changes

The primary material change disclosed is the update to the company's investor presentation materials. The updated presentation, attached as Exhibit 99.1, reflects new information that management intends to use in meetings with investors. No financial or operational changes are detailed within the body of this specific 8-K filing.

Guidance, Outlook, and Risks

Management commentary is limited to the notification that the attached investor presentation has been updated. The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section. Consequently, specific guidance, outlook, or risk factors are not detailed in this text but are contained within the referenced Exhibit 99.1.

Key Facts for Investor Verification

  • Review Exhibit 99.1 (Investor Presentation dated November 10, 2022) for the specific updated data and strategic outlook.
  • Note that the updated presentation materials are not legally "filed" and are not incorporated by reference into other SEC filings unless expressly stated.
  • Verify the company's status as an emerging growth company, which may impact financial reporting standards.
  • Confirm the trading symbol "IPSC" on the Nasdaq Global Select Market for current stock performance.

Nachrichten